Patrick Phillips

Has grant

Assistant Professor

University of California, San Francisco

United States

Research Interests

Explore related searches

Professors in United States

Contact this professor

Get a free first email built on one of their papers, ready for you to edit and send yourself.

About

Dr. Patrick Phillips is an Assistant Professor at the University of California San Francisco, USA. His research primarily focuses on tuberculosis treatment, including the efficacy and safety of levofloxacin for multidrug-resistant tuberculosis and risk-stratified approaches for drug-susceptible pulmonary tuberculosis. Recent publications highlight his contributions to optimizing treatment dosages and analyzing clinical trial data related to tuberculosis. Dr. Phillips continues to advance knowledge in the field through rigorous clinical research and analysis.

Recent Grants

Grant: Close

Tuberculosis Treatment Trials

Open Date: 2015-03-01

Close Date:

Grant: Close

Design of Trials, Meta-analyses and observational studies

Open Date: 2015-03-01

Close Date:

Grant: Close

Two-month Regimens Using Novel Combinations to Augment Treatment Effectiveness for drug-sensitive Tuberculosis: the "TRUNCATE-TB" trial

Open Date: 2014-11-14

Close Date: 2019-11-13

Grant: Close

Two-month Regimens using novel Combinations to Augment Treatment effectiveness for drug-sensitive Tuberculosis: the "TRUNCATE-TB" trial.

Open Date: 2014-11-14

Close Date: 2019-11-13

Grant: Close

A randomized trial of therapy shortening for minimal tuberculosis with new WHO-recommended doses and FDC drugs in African/Indian HIV+/HIV- children

Open Date: 2014-09-30

Close Date: 2018-09-29

Articles (19)

Year:

2025

Year:

2025

Year:

2025

Year:

2025

Year:

2024

Year:

2024

Year:

2024

Year:

2024

Year:

2023

Year:

2023

Year:

2023

Year:

2023

Year:

2023

Year:

2022

Year:

2021

Year:

2021

Year:

2021

Year:

2021

Year:

2020

Collaborators (7)

Geraint Davies

Professor of Infection Pharmacology

University of Liverpool

UNITED KINGDOM

View details

Jason Stout

Duke University

UNITED STATES

View details

Ruth L Goodall

University College London

UNITED KINGDOM

View details

Tra My Pham

UNITED KINGDOM

View details

Raquel Duarte3,8,9,10

PORTUGAL

View details

Ulrika S. H. Simonsson

Uppsala University

SWEDEN

View details

Thomas Harrison

UNITED KINGDOM

View details

ApplyKite TwinLearns as you apply

Make your next move.

Prepare your application

Review drafts before you send them.

Patrick Phillips

Research Interests

Explore related searches

Contact this professor

About

Recent Grants

Articles (19)

Reply to Liao et al.: Optimizing Levofloxacin Dosing for MDR-TB in Low Fat-Free Mass Asian Populations

Efficacy and Safety of Higher Doses of Levofloxacin for Multidrug-resistant Tuberculosis: A Randomized, Placebo-controlled Phase II Clinical Trial

Author Correction: Risk-stratified treatment for drug-susceptible pulmonary tuberculosis

Analysis of time-to-positivity data in tuberculosis treatment studies: Identifying a new limit of quantification

Pyrazinamide Safety, Efficacy, and Dosing for Treating Drug-Susceptible Pulmonary Tuberculosis: A Phase 3, Randomized, Controlled Clinical Trial

Estimands for clinical endpoints in tuberculosis treatment randomized controlled trials: a retrospective application in a completed trial

Adverse Events Reported During Weekly Isoniazid-Rifapentine (3HP) Tuberculosis Preventive Treatment Among People With Human Immunodeficiency Virus in Uganda

Risk-stratified treatment for drug-susceptible pulmonary tuberculosis

Handling intercurrent events and missing data in non-inferiority trials using the estimand framework: A tuberculosis case study

A Standardized Approach for Collection of Objective Data to Support Outcome Determination for Late-Phase Tuberculosis Clinical Trials

Early bactericidal activity studies for pulmonary tuberculosis: A systematic review of methodological aspects

To Err Is Human, to Forgive Is Pharmacodynamic

Treatment-shortening regimens for tuberculosis: updates and future priorities

Rethinking intercurrent events in defining estimands for tuberculosis trials

A systematic review of endpoint definitions in late phase pulmonary tuberculosis therapeutic trials

Precision-Enhancing Risk Stratification Tools for Selecting Optimal Treatment Durations in Tuberculosis Clinical Trials

Increased bactericidal activity but dose-limiting intolerability at 50 mg·kg−1 rifampicin

Optimising pyrazinamide for the treatment of tuberculosis

Optimizing the Design of Latent Tuberculosis Treatment Trials: Insights from Mathematical Modeling

Collaborators (7)

Geraint Davies

Jason Stout

Ruth L Goodall

Tra My Pham

Raquel Duarte3,8,9,10

Ulrika S. H. Simonsson

Thomas Harrison

Make your next move.